Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
NAMS Stock — NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS)
Updated October 16, 2026.
NAMS is a Stock. Total return is 83.6% over the past 5.7 years, 27.4 points behind SPY at 111.0%.
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company developing therapies for cardiometabolic disease, with its lead candidate Obicetrapib—an oral CETP inhibitor in clinical trials for lowering LDL cholesterol in cardiovascular disease and also being evaluated in Phase 2a testing for Alzheimer's disease. The company does not currently distribute to shareholders. This stock appeals to investors seeking exposure to clinical-stage pharmaceutical development with no expectation of near-term income.
NAMS performance versus SPY
Price and return data through 2026-10-16.
Total return is 83.6% over the past 5.7 years, 27.4 points behind SPY at 111.0%. Over the past year its total return — price change plus distributions reinvested — is -45.6%. Its deepest 1-year drawdown was 52.2%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -6.4% | — |
| 3M | -36.1% | — |
| 6M | -40.3% | — |
| YTD | -43.5% | — |
| 1Y | -45.6% | — |
| 2Y CAGR | — | 2.20% |
| 3Y CAGR | — | 37.60% |
| 5Y CAGR | — | 15.20% |
| Since inception (5.7 years) | 83.6% | 11.30% |
NAMS key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 02/08/2021
- Distribution frequency
- None
- Last close
- $19.83 (as of 2026-10-16)
- Market cap
- $2,318,205,904
- Average volume
- 1937146.0
- Beta
- 0.1
- Payout ratio
- 0.0%
- Forward P/E
- 119.0476
- EPS
- $-2.16
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
NAMS risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 52.2%.
Who may consider NAMS — and who may not
It is a weaker fit for investors who need monthly cash flow (NAMS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on NAMS
Frequently asked questions
Does NAMS pay monthly?
No. NAMS does not currently distribute.
When does NAMS pay a dividend?
NAMS does not currently distribute.
How has NAMS performed?
Total return is 83.6% over the past 5.7 years, 27.4 points behind SPY at 111.0%. Over the past year its total return — price change plus distributions reinvested — is -45.6%. Its deepest 1-year drawdown was 52.2%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.